Upstream Bio, Inc. (UPB) Price & Analysis

Compare

151 Followers

UPB Stock Chart & Stats

$24.94

-$0.08(-0.49%)

At close: Jan 08 4:00 PM EST

$24.94

-$0.08(-0.49%)

Day’s Range― - ―

52-Week Range$5.14 - $26.90

Previous CloseN/A

Volume32.37K

Average Volume (3M)433.44K

Market Cap

$1.35B

Enterprise Value$198.38M

Total Cash (Recent Filing)$372.43M

Total Debt (Recent Filing)$1.42M

Price to Earnings (P/E)―

Beta0.71

Next Earnings

Mar 18, 2026

EPS Estimate

-0.71

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.63

Shares Outstanding53,909,428

10 Day Avg. Volume348,822

30 Day Avg. Volume433,444

Financial Highlights & Ratios

PEG Ratio-0.32

Price to Book (P/B)1.80

Price to Sales (P/S)356.14

P/FCF Ratio-14.14

Enterprise Value/Market Cap0.15

Enterprise Value/Revenue70.88

Enterprise Value/Gross Profit71.67

Enterprise Value/Ebitda-1.46

Forecast

1Y Price Target

$57.50

Price Target Upside130.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsRecent positive clinical results from the VIBRANT Ph2 trial in CRSwNP further validate verekitug’s potential.

Efficacy And DosingIf verekitug demonstrates efficacy and safety similar to Tezspire, but with fewer injections per year, there could be wide adoption leading to commercial success.

Investment ProfileWith a unique investment profile of a solid, well financed, differentiated, and validated asset with a great management team and another key catalyst, this stock is seen as an overlooked gem among small cap biotechs.

Bears Say

Competitive PressureVerekitug may fail to produce competitive data or other TSLP and novel approaches in the clinic may raise the bar.

Efficacy StandardsInvestors have debated whether the Phase II or Phase III results with Tezspire should serve as the 'bar' for efficacy for verekitug.

Trial ChallengesThere are nuances to measuring and analyzing change in NPS in clinical trials that make cross-trial comparisons difficult.

Upstream Bio, Inc. News

Upstream Bio initiated with an Outperform at Evercore ISI

Evercore ISI analyst Cory Kasimov initiated coverage of Upstream Bio (UPB) with an Outperform rating and $40 price...

3d ago

UPB

3 Best Biotech Stocks to Buy Now, 11/12/2025, According to Top Analysts

Looking for top-rated biotech stocks to buy now? Recent analyst updates highlight three companies that have earned Strong...

9d ago

UPB

BNTX

Upstream Bio files automatic mixed securities shelf

07:38 EST Upstream Bio (UPB) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

16d ago

UPB

Upstream Bio reports Q3 revenue $683k, consensus $516.8k

“During this quarter we reached an important milestone in verekitug’s development and shared positive top-line results from VIBRANT,...

16d ago

UPB

Upstream Bio, Inc.’s Verekitug: A Promising Buy with Blockbuster Potential in Asthma and COPD Markets

Upstream Bio, Inc. (UPB) has received a new Buy rating, initiated by Evercore ISI analyst, Cory Kasimov. Cory...

3d ago

UPB

Upstream Bio Reports Progress in Respiratory Trials

Upstream Bio, Inc. ( ($UPB) ) has released its Q3 earnings. Here is a breakdown of the information...

15d ago

UPB

Promising Outlook for Upstream Bio, Inc. Driven by Strong Drug Developments and Financial Health

TD Cowen analyst Yaron Werber has maintained their bullish stance on UPB stock, giving a Buy rating today....

15d ago

UPB

Upstream Bio, Inc. Receives Buy Rating Due to Promising Clinical Trial Results and Strong Drug Pipeline

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on...

15d ago

UPB

Upstream Bio’s Promising Trials and Strategic Outlook Drive Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on UPB stock, giving a Buy rating on...

22d ago

UPB

Upstream Bio’s COPD Study: A Potential Game-Changer for Investors

Upstream Bio, Inc. (($UPB)) announced an update on their ongoing clinical study. Upstream Bio, Inc. (UPB) is conducting...

24d ago

UPB

Upstream Bio’s Verekitug Study: A Potential Game-Changer for Severe Asthma Treatment

Upstream Bio, Inc. (($UPB)) announced an update on their ongoing clinical study. Upstream Bio, Inc. is conducting a...

24d ago

UPB

Upstream Bio initiated with a Buy at Truist

Truist initiated coverage of Upstream Bio (UPB) with a Buy rating and $47 price target Verekitug offers similarly...

1M ago

UPB

Upstream Bio management to meet with Piper Sandler

Meeting to be held in Connecticut on October 15 and in New York on October 16 hosted by...

1M ago

UPB

Upstream Bio’s verekitug shows prevention of TSLP binding in respiratory disease

Upstream Bio (UPB) presented structural and mechanistic data showing verekitug’s potent pharmacodynamic activity through its approach of targeting...

2M ago

UPB

UPB FAQ

What was Upstream Bio, Inc.’s price range in the past 12 months?

Upstream Bio, Inc. lowest stock price was $5.14 and its highest was $26.90 in the past 12 months.

What is Upstream Bio, Inc.’s market cap?

Upstream Bio, Inc.’s market cap is $1.35B.

When is Upstream Bio, Inc.’s upcoming earnings report date?

Upstream Bio, Inc.’s upcoming earnings report date is Mar 18, 2026 which is in 117 days.

How were Upstream Bio, Inc.’s earnings last quarter?

Upstream Bio, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$0.682 by $0.052.

Is Upstream Bio, Inc. overvalued?

According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Upstream Bio, Inc. pay dividends?

Upstream Bio, Inc. does not currently pay dividends.

What is Upstream Bio, Inc.’s EPS estimate?

Upstream Bio, Inc.’s EPS estimate is -0.71.

How many shares outstanding does Upstream Bio, Inc. have?

Upstream Bio, Inc. has 53,909,428 shares outstanding.

What happened to Upstream Bio, Inc.’s price movement after its last earnings report?

Upstream Bio, Inc. reported an EPS of -$0.63 in its last earnings report, beating expectations of -$0.682. Following the earnings report the stock price went down -1.293%.

Which hedge fund is a major shareholder of Upstream Bio, Inc.?

Currently, no hedge funds are holding shares in UPB

Upstream Bio, Inc. Stock Smart Score

Neutral

Company Description

Upstream Bio, Inc.

Upstream Bio, Inc. (UPB) is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company operates primarily in the biopharmaceutical sector, specializing in the research and development of novel treatments for various diseases, particularly in the fields of oncology and autoimmune disorders. Upstream Bio aims to leverage its proprietary technology platform to advance its pipeline of drug candidates, ultimately seeking to improve patient outcomes through targeted therapies.

Upstream Bio, Inc. (UPB) Earnings & Revenues

Historic Earnings Reports

UPB Stock 12 Month Forecast

Average Price Target

$57.50

▲(130.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","76":"$76","22.75":"$22.8","40.5":"$40.5","58.25":"$58.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,22.75,40.5,58.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.85,29.630769230769232,33.41153846153846,37.19230769230769,40.973076923076924,44.753846153846155,48.534615384615385,52.315384615384616,56.09615384615385,59.87692307692308,63.65769230769231,67.43846153846154,71.21923076923076,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.85,28.284615384615385,30.71923076923077,33.15384615384615,35.58846153846154,38.02307692307692,40.45769230769231,42.892307692307696,45.32692307692308,47.761538461538464,50.19615384615385,52.63076923076923,55.065384615384616,{"y":57.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.85,26.93846153846154,28.02692307692308,29.115384615384617,30.203846153846154,31.292307692307695,32.38076923076923,33.46923076923077,34.55769230769231,35.64615384615385,36.73461538461538,37.823076923076925,38.91153846153846,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.76,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":24.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >